News Detail
WASHINGTON, 1 MAY 2024: the Federal Trade Commission expanded its campaign against pharmaceutical manufacturers’ improper or inaccurate listing of patents in the Food and Drug Administration’s (FDA) Orange Book, disputing junk patent listings for diabetes, ......
View Details
Source : Federal Trade Commission
Ozempic
pharmaceutical industry practices
Federal Trade Commission
warning letters
Novo Nordisk
GlaxoSmithKline
AstraZeneca
Related News
- UK regulator probes anti-depressants safety alerts after suicide link (12-12-2024)
- Haryana Food Department to Crack Down on Fake Protein Supplements After Major Bust (12-12-2024)
- Drug inspector sentenced to 3-yr rigorous imprisonment (12-12-2024)
- 11.12 crore worth of short-shelf life medicines expired due to delayed supply to TNMSC: CAG Report (12-12-2024)
- Ayush Ministry amends D&C Act to add Homoeopathy, Sowa Rigpa books and Pharmacopoeias (12-12-2024)
- Construction of all three bulk drug parks are in progress: Ministry of chemicals (12-12-2024)
- Four-member gang nabbed for selling ‘Mephentermine Sulphate’ injections in Hyderabad (12-12-2024)
- Combining BCL-2 and BTK inhibitors shows promise in chronic lymphocytic leukemia (CLL) (11-12-2024)
- Punjab cop arrests man for narcotic drugs case, gets fined by court (11-12-2024)
- NPPA Mandates Transparency in Angioplasty Billing with Separate Costs for Non-Stent Components: MoS Anupriya Patel (11-12-2024)